Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Plos One
|
February 11, 2016
Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials
Dominic Magirr, Thomas Jaki, Franz Koenig, et al.
Pharmaceutical Statistics
|
May 6, 2024
Visualizing hypothesis tests in survival analysis under anticipated delayed effects
José L Jiménez, Isobel Barrott, Francesca Gasperoni, et al.
Statistical Methods in Medical Research
|
April 1, 2020
Optimized multiple testing procedures for nested sub-populations based on a continuous biomarker
Alexandra Christine Graf, Dominic Magirr, Alex Dmitrienko, et al.
Trials
|
November 18, 2015
Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups
Annabel Allison, Tansy Edwards, Raymond Omollo, et al.
Cancer Chemotherapy and Pharmacology
|
February 14, 2019
Phase I study of orally administered <sup>14</sup>Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
Alexander MacDonald, Graeme Scarfe, Dominic Magirr, et al.
British Journal of Haematology
|
August 22, 2014
Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study
Sophie Brunner-Ziegler, Bernd Jilma, Dominic Magirr, et al.
BMC Medical Research Methodology
|
August 15, 2022
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Plos One
|
February 11, 2016
Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials
Dominic Magirr, Thomas Jaki, Franz Koenig, et al.
Pharmaceutical Statistics
|
May 6, 2024
Visualizing hypothesis tests in survival analysis under anticipated delayed effects
José L Jiménez, Isobel Barrott, Francesca Gasperoni, et al.
Statistical Methods in Medical Research
|
April 1, 2020
Optimized multiple testing procedures for nested sub-populations based on a continuous biomarker
Alexandra Christine Graf, Dominic Magirr, Alex Dmitrienko, et al.
Trials
|
November 18, 2015
Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups
Annabel Allison, Tansy Edwards, Raymond Omollo, et al.
Cancer Chemotherapy and Pharmacology
|
February 14, 2019
Phase I study of orally administered <sup>14</sup>Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
Alexander MacDonald, Graeme Scarfe, Dominic Magirr, et al.
British Journal of Haematology
|
August 22, 2014
Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study
Sophie Brunner-Ziegler, Bernd Jilma, Dominic Magirr, et al.
BMC Medical Research Methodology
|
August 15, 2022
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman, et al.
Page
of 2